PTKFF Stock - PT Kalbe Farma Tbk.
Unlock GoAI Insights for PTKFF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $32.63T | $30.45T | $28.93T | $26.26T | $23.11T |
| Gross Profit | $12.96T | $11.55T | $11.70T | $11.28T | $10.25T |
| Gross Margin | 39.7% | 37.9% | 40.5% | 43.0% | 44.3% |
| Operating Income | $4.07T | $3.63T | $4.49T | $4.16T | $3.64T |
| Net Income | $3.24T | $2.77T | $3.38T | $3.18T | $2.73T |
| Net Margin | 9.9% | 9.1% | 11.7% | 12.1% | 11.8% |
| EPS | $70.22 | $59.81 | $72.71 | $67.92 | $58.31 |
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
Visit WebsiteEarnings History & Surprises
PTKFFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q4 2025 | Oct 27, 2025 | $0.00 | $0.00 | 0.0% | = MET |
Q2 2025 | Apr 29, 2025 | $0.00 | $23.33 | +1927999.2% | ✓ BEAT |
Q4 2024 | Dec 31, 2024 | — | $18.68 | — | — |
Q4 2024 | Oct 30, 2024 | $0.00 | $12.42 | +1254445.5% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.00 | $18.33 | +1779511.7% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $0.00 | $20.70 | +1815689.5% | ✓ BEAT |
Q4 2023 | Dec 30, 2023 | — | $15.17 | — | — |
Q3 2023 | Sep 30, 2023 | $0.00 | $11.59 | +1016566.7% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $0.00 | $14.56 | +1102930.3% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $0.00 | $18.40 | +1426256.6% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $19.39 | — | — |
Q4 2022 | Oct 31, 2022 | $18.68 | $18.33 | -1.9% | ✗ MISS |
Q3 2022 | Jul 29, 2022 | $18.79 | $17.26 | -8.1% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $18.30 | $17.85 | -2.5% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $19.22 | — | — |
Q4 2021 | Oct 25, 2021 | $15.11 | $16.87 | +11.6% | ✓ BEAT |
Q3 2021 | Jul 30, 2021 | $15.84 | $16.65 | +5.1% | ✓ BEAT |
Q2 2021 | May 3, 2021 | $14.74 | $15.29 | +3.7% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | — | $15.06 | — | — |
Latest News
Frequently Asked Questions about PTKFF
What is PTKFF's current stock price?
What is the analyst price target for PTKFF?
What sector is PT Kalbe Farma Tbk. in?
What is PTKFF's market cap?
Does PTKFF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PTKFF for comparison